MARK MCDADE
CIK 1242126 · CEO · last filed 2025-10-28
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$47.2K
Companies
10
Total Filings
51
Lifetime Open-Market Net
$1.79M
Filer Profile
Reported Address
QIMING US11100 NE 8TH STREET
BELLEVUE, WA 98004
Related Filers
PDL BIOPHARMA, INC. — 45 joint filings, latest 2007-07-24
Qiming U.S. Healthcare Fund II, L.P. — 4 joint filings, latest 2023-04-11
Qiming U.S. Healthcare GP II, LLC — 4 joint filings, latest 2023-04-11
GARY E RIESCHEL — 1 joint filings, latest 2023-04-11
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Tourmaline Bio, Inc. (TRML) Delisted | Director | 0 | $47.98 | $0 | $3.25M | 4 | 2025-10-28 |
| Icosavax, Inc. (ICVX) Delisted | Director | 0 | $15.31 | $0 | $299.8K | 4 | 2024-02-20 |
| Tourmaline Bio, Inc. (TALS) Delisted | Director | — | $27.20 | — | $0 | 2 | 2023-06-14 |
| COLL | Director | 0 | $23.53 | $0 | $0 | 6 | 2020-10-14 |
| DERM | Director | 6,000 | $7.86 | $47.2K | $0 | 6 | 2019-06-14 |
| FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Director | 10,162 | $178.75 | $1.82M | $0 | 4 | 2018-05-14 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Director | — | $38.00 | — | $0 | 2 | 2016-03-17 |
| Aimmune Therapeutics, Inc. (AIMT) Delisted | Director | 16,660 | — | — | $266.6K | 1 | 2015-08-11 |
| CYTK | Director | — | $72.72 | — | $0 | 4 | 2009-05-22 |
| PDL BIOPHARMA, INC. (PDLI) Delisted | CEO | 46,275 | — | — | -$2.03M | 9 | 2007-07-24 |
Recent Filings · Page 6 of 6
51 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2007-01-04 | PDL BIOPHARMA, INC. (PDLI) Delisted | Mixed | — | -$239.9K | EDGAR |
Showing 51–51 of 51
Prev
Page 6 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.